ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was down 6.9% during mid-day trading on Wednesday . The company traded as low as GBX 4.50 ($0.06) and last traded at GBX 4.66 ($0.06). Approximately 4,119,310 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 22,171,900 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Stock Performance
The company has a fifty day moving average price of GBX 2.28 and a 200-day moving average price of GBX 1.89. The firm has a market capitalization of £19.39 million, a PE ratio of -465.50 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What is the Shanghai Stock Exchange Composite Index?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- When to Sell a Stock for Profit or Loss
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
